NCT04645069 - ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 15, 2021

Primary Completion Date

January 29, 2024

Study Completion Date

May 17, 2024

Conditions

Advanced/Metastatic Solid Tumors

Interventions

BIOLOGICAL

ADG126 Mono

ADG126 will be administered as an IV infusion over 30-60 minutes ± 15 minutes.

BIOLOGICAL

ADG126-anti PD1

ADG126-toripalimab combination regimen will receive of toripalimab 15 to 30 minutes after the end of the ADG126 infusion

BIOLOGICAL

ADG126-ADG106

ADG126-ADG106 combination regimen will be receive of ADG106 15 to 30 minutes after the end of the ADG126 infusion

Trial Locations (9)

Southside Cancer Care Centre, Miranda

Cabrini Health Limited, Malvern

Sunshine Coast University Private Hospital, Birtinya

One Clinical Research Pty Ltd, Nedlands

Next oncology, San Antonio

University of California Los Angeles, Los Angeles

National University Hospital, Singapore

National Cancer Centre Singapore, Singapore

Macquarie University Hospital, Sydney